An orthotopic neobladder is a urinary diversion created after radical cystectomy by reshaping a segment of small intestine into an internal reservoir and connecting it to the urethra. Urine can then pass through the natural urinary channel rather than an abdominal stoma. A neobladder does not behave exactly like the original bladder: the bowel reservoir has no normal bladder nerves or contraction, so patients learn timed voiding using pelvic-floor relaxation and gentle abdominal pressure. Night-time leakage is common early and can persist in some patients, while others may have incomplete emptying and need intermittent self-catheterisation. Good selection and realistic counselling are more important than simply wanting to avoid a bag.

Who may be suitable?

• Cancer can be removed with a urethra that is oncologically safe to retain.
• Kidney and liver function are adequate for the metabolic load of a continent bowel reservoir.
• No major bowel condition prevents use of the required intestinal segment.
• Patient has sufficient dexterity, cognition and motivation to learn timed voiding and self-catheterisation if required.
• Baseline continence and pelvic-floor function are reasonably favourable.

Who may not be a good candidate?

Contraindications or strong cautions include urethral tumour involvement, poor renal or hepatic function, significant bowel disease, inability to self-catheterise, severe cognitive impairment and situations where cancer factors require urethrectomy. Age alone is not the only criterion; functional status matters more.

Learning to void after surgery

• Initially void on a strict timed schedule, including at night.
• Sit or stand comfortably, relax the pelvic floor and use gentle abdominal pressure rather than straining hard.
• Check post-void residual when advised to make sure the reservoir empties adequately.
• Learn intermittent self-catheterisation if residual urine remains high or retention occurs.
• Increase reservoir capacity gradually according to the surgical team’s plan rather than intentionally overdistending it.

Continence expectations

Daytime continence improves as capacity and sphincter coordination recover. Night-time continence is more challenging because the intestinal reservoir lacks normal bladder sensation and urine production continues while asleep. Setting alarms to void and avoiding excessive late-night fluid can help, but some patients continue to use a pad at night long term.

Common long-term issues

Neobladder vs ileal conduit

A neobladder avoids an external appliance but is more demanding to manage. An ileal conduit is simpler and usually empties predictably into a bag, while a neobladder requires active training and may involve incontinence or catheterisation. The “best” diversion is the one that is safe, durable and fits the patient’s medical condition and priorities.

How a neobladder is created

After the bladder is removed, a longer segment of small intestine is reshaped into a low-pressure reservoir and connected to the urethra. The ureters are connected to the reservoir so urine can pass through the urethra again. A neobladder does not reproduce a normal bladder: bowel does not have the same nerves or muscle behaviour, so patients learn to empty by schedule, pelvic-floor relaxation and gentle abdominal pressure rather than relying only on a normal urge.

Catheters and sometimes ureteric stents remain temporarily while the joins heal. Once removed, capacity and continence improve gradually as the reservoir stretches. Regular emptying is important, especially early, because overdistension can impair emptying and continence.

What daily life is like after neobladder surgery

Daytime continence is often achieved earlier than night-time continence. Many patients use timed voiding and an alarm at night initially. Some remain dependent on pads at night, and a minority need clean intermittent catheterisation because the reservoir does not empty adequately. Mucus in urine is normal because the reservoir is made from intestine; irrigation may be taught during the early period when mucus is heavy.

Long-term surveillance includes cancer follow-up as well as kidney function, electrolytes, acid-base balance, vitamin B12 when appropriate and assessment for infection, stones or narrowing at the ureteric joins. A neobladder can provide an excellent quality of life for a motivated, appropriately selected patient, but it requires more active participation than an ileal conduit.

What patients often underestimate before choosing a neobladder

A neobladder removes the external pouch, but it replaces it with a different set of responsibilities. The reservoir must be emptied on schedule, night-time continence usually takes longer than daytime continence, mucus production is expected, and some patients need intermittent self-catheterisation. These are not signs that the operation has “failed”; they are part of how an intestinal reservoir can behave.

The best candidate is therefore not simply the youngest patient. Motivation, dexterity, kidney function, urethral cancer status, bowel health, cognition and willingness to catheterise if needed are central to selection.

Consultation checklist

• Cancer stage and urethral-margin assessment plan.
• Kidney and liver function.
• Bowel history, inflammatory bowel disease or previous bowel surgery.
• Baseline continence and ability to perform self-catheterisation.
• Home support and willingness to follow timed voiding.
• After surgery: residual urine measurements, electrolytes/creatinine and infection history.

FAQs

Related reading

• Radical Cystectomy Explained
• Ileal Conduit Explained
• Muscle-Invasive Bladder Cancer
• Bladder Cancer: Symptoms, Diagnosis and Treatment
• Repeat TURBT: Why Is a Second Surgery Sometimes Needed?
• Urologist in Latur

References

• European Association of Urology (EAU). EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. 2026 edition https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer
• British Association of Urological Surgeons (BAUS). Radical cystectomy and urinary diversion patient information https://www.baus.org.uk/
• National Cancer Institute. Bladder Cancer Treatment (PDQ®)–Patient Version https://www.cancer.gov/types/bladder/patient/bladder-treatment-pdq
• American Urological Association/ASCO/ASTRO/SUO. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer Guideline (2017; amended 2024) https://www.auanet.org/guidelines-and-quality/guidelines/muscle-invasive-bladder-cancer